Johnson & Johnson is discontinuing its talc-based baby powder in the US and Canada

Sales of Johnson &Johnson's talc-based baby power have dropped by 60% over the last three years after mounting litigation that the product causes various forms of cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 30 May 2020Source: Life SciencesAuthor(s): Qi Fu, Zhenhai Yu
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 29 May 2020Source: Life SciencesAuthor(s): Nagesh Kishan Panchal, E.P. Sabina
Source: Life Sciences - Category: Biology Source Type: research
In this study, five machine learning algorithms and twelve types of molecular fingerprints were employed to generate QSAR discriminant models for mitochondrial toxicity. A threshold moving method was adopted to resolve the imbalance issue in the training data. Consensus of the models by an averaging probability strategy improved prediction performance. The best model has correct classification rates of 81.8% and 88.3% in ten-fold cross validation and external validation, respectively. Substructures such as phenol, carboxylic acid, nitro and arylchloride were found informative through analysis of information gain and freque...
Source: Chemosphere - Category: Chemistry Authors: Tags: Chemosphere Source Type: research
This study is aimed at determining the prevalence of severe depression in Iranian women with breast...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Publication date: Available online 30 May 2020Source: European Journal of Surgical OncologyAuthor(s): R.H. Bhogal, P.H. Patel, S.L.F. Doran, S. Zar, J.M. Pollok, L.R. Jiao, W.H. Allum, M.A. Chaudry, S. Kumar
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Publication date: Available online 29 May 2020Source: Respiratory InvestigationAuthor(s): Yoshiaki Kinoshita, Hiroshi Ishii, Yoshinobu Eishi, Keisuke Uchida, Masayo Yoshimura, Akinori Iwasaki, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Authors: Lucioni M, Lionello M, Guida F, Sovran F, Canal F, Rizzotto G, Bertolin A PMID: 32469004 [PubMed - in process]
Source: Acta Otorhinolaryngologica Italica - Category: ENT & OMF Tags: Acta Otorhinolaryngol Ital Source Type: research
Authors: Fu J, Kim YJ Abstract With the rapid approval of immune checkpoint inhibitors for lung, melanoma, breast, genitourinary, and hematological malignancies, the hematopoietic cells in the tumor microenvironment (TME) are now considered an important, if not essential, consideration for cancer scientists. In many instances, syngeneic murine models have not been highly predictive for responsiveness in clinical trials. Our limited understanding of the human TME have, therefore, precluded a rational translation of immunotherapeutic combinations. This has led to the adoption of hematopoietic humanized murine models ...
Source: Current Protocols in Pharmacology - Category: Drugs & Pharmacology Tags: Curr Protoc Pharmacol Source Type: research
Conclusions Opportunistic salpingectomy holds promise as a risk-reducing intervention for ovarian cancer. The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology recommend that physicians counsel average-risk women regarding opportunistic salpingectomy when planning pelvic surgery. Randomized controlled trials are needed to evaluate long-term implications of salpingectomy. Urogynecologic surgeons should discuss salpingectomy as part of surgical informed consent. Vaginal salpingectomy should be incorporated into residency and fellowship training programs.
Source: Female Pelvic Medicine and Reconstructive Surgery - Category: OBGYN Tags: Review Article Source Type: research
We report a case of successful desensitization therapy after osimertinib-induced urticaria. An 85-year-old Japanese woman received osimertinib as third-line therapy for NSCLC with the EGFR T790M mutation. After two days, she developed urticaria of the lower extremities. We started osimertinib desensitization therapy at 0.1 mg/day, which was gradually increased to 40 mg/day. She continued osimertinib for>12 months without adverse effects. Desensitization therapy with osimertinib could be useful for patients experiencing osimertinib-induced urticaria. PMID: 32461525 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
More News: Babies | Canada Health | Cancer | Cancer & Oncology | Health